Fidelis Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Fidelis Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	27,994 +857	+3%	+$49.2K	0.09%	174
2026 Q1	$1.65M	Buy	27,137 +4,292	+19%	+$250K	0.12%	151
2025 Q4	$1.23M	Buy	22,845 +2,420	+12%	+$116K	0.09%	178
2025 Q3	$921K	Sell	20,425 -1,353	-6%	-$63.2K	0.07%	212
2025 Q2	$976K	Sell	21,778 -1,215	-5%	-$59.6K	0.09%	176
2025 Q1	$1.1M	Buy	22,993 +10,099	+78%	+$589K	0.12%	144
2024 Q4	$773K	Buy	12,894 +813	+7%	+$45.4K	0.08%	193
2024 Q3	$641K	Sell	12,081 -987	-8%	-$46.3K	0.08%	207
2024 Q2	$608K	Buy	13,068 +6,007	+85%	+$269K	0.09%	190
2024 Q1	$383K	Buy	7,061 +239	+4%	+$12.2K	0.06%	246
2023 Q4	$350K	Buy	6,822 +2,491	+58%	+$131K	0.08%	221
2023 Q3	$251K	Sell	4,331 -2,014	-32%	-$123K	0.09%	223
2023 Q2	$406K	Buy	6,345 +319	+5%	+$21.4K	0.15%	155
2023 Q1	$411K	Buy	+6,026	New	+$425K	0.17%	141

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelis Capital Partners's BMY Position: Q2 2026 in Review

Fidelis Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 3.2% in Q2 2026, buying an estimated $49.2K and bringing the position to 27,994 shares worth $1.61M. The position accounts for 0.09% of the portfolio, ranked #174.

Fidelis Capital Partners first reported a position in BMY in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.65M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Fidelis Capital Partners held 27,994 shares of Bristol-Myers Squibb worth $1.61M as of Q2 2026.
Fidelis Capital Partners bought 857 Bristol-Myers Squibb shares in Q2 2026, an estimated $49.2K.
Bristol-Myers Squibb made up 0.09% of Fidelis Capital Partners's portfolio in Q2 2026, its #174 holding.
Fidelis Capital Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 14 quarters since.
Fidelis Capital Partners's Bristol-Myers Squibb position peaked at $1.65M in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.